Fate Therapeutics (FATE) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Humacyte (HUMA) over the past year, losing 10.8% versus a loss of 63.5%. Over five years, HUMA leads with a -95.9% price change compared with -98.3% for FATE. Humacyte is the larger company by market cap ($123.7 million vs $111.8 million), about 1.1 times the size.
Humacyte converts more of its revenue into profit, with a net margin of -2003.6% versus -2051.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | HUMA |
|---|---|---|
| Share price | $0.919 | $0.4454 |
| Market cap | $111.82M | $123.73M |
| 1-day change | -9.01% | -17.90% |
| YTD return | -6.22% | -53.65% |
| 1-year return | -10.78% | -63.49% |
| 5-year return | -98.25% | -95.94% |
| EPS (TTM) | $-1.03 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.65M | $2.04M |
| Revenue growth (YoY) | -51.24% | — |
| Net income (latest FY) | $-136.31M | $-40.83M |
| Gross margin | — | -376.05% |
| Operating margin | -2222.45% | -5306.04% |
| Net margin | -2051.08% | -2003.58% |
| 52-week high | $3.23 | $1.53 |
| 52-week low | $0.90 | $0.337 |
| Distance from 52-week high | -71.55% | -70.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +522.42% | +268.21% |
| Average volume | 1.53M | 5.36M |
| Shares outstanding | 121.67M | 277.80M |
| Employees | 161 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed HUMA by 52.7 percentage points over the past year.
- Humacyte is more profitable, keeping -2003.6 cents of every revenue dollar as net income versus -2051.1 cents for Fate Therapeutics.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
FATE vs HUMA FAQ
Which is bigger, Fate Therapeutics or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $123.73M compared with $111.82M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, FATE or HUMA?
FATE returned -10.78% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.